Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Biliary Tract Cancers

NCT04072445 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04072445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04072445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Biliary Tract Cancers
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
October 18, 2019
Completion date
August 13, 2021
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced bile duct carcinoma, advanced gallbladder carcinoma, refractory bile duct carcinoma, refractory gallbladder carcinoma, stage iii distal bile duct cancer ajcc v8, stage iii gallbladder cancer ajcc v8, stage iii intrahepatic bile duct cancer ajcc v8, stage iiia distal bile duct cancer ajcc v8, stage iiia gallbladder cancer ajcc v8, stage iiia intrahepatic bile duct cancer ajcc v8, stage iiib distal bile duct cancer ajcc v8, stage iiib gallbladder cancer ajcc v8, stage iiib intrahepatic bile duct cancer ajcc v8, stage iv distal bile duct cancer ajcc v8, stage iv gallbladder cancer ajcc v8, stage iv intrahepatic bile duct cancer ajcc v8, stage iva gallbladder cancer ajcc v8, stage ivb gallbladder cancer ajcc v8